Optimising occupational performance through sensory modulation interventions: Case reports of two young adults diagnosed with juvenile Huntington's disease

2015 ◽  
Vol 78 (12) ◽  
pp. 767-771 ◽  
Author(s):  
Anahita Brown ◽  
Caroline Fisher
2020 ◽  
Vol 14 (1) ◽  
Author(s):  
Sigita Lesinskienė ◽  
Darja Rojaka ◽  
Rūta Praninskienė ◽  
Aušra Morkūnienė ◽  
Aušra Matulevičienė ◽  
...  

Abstract Background Huntington’s disease is a rare, autosomal dominant neurodegenerative disease characterized by motor, cognitive, and psychiatric symptoms. Usually, the disease symptoms first appear around the age of 40, but in 5–10% of cases, they manifest before the age of 21. This is then referred to as juvenile Huntington’s disease. According to the small number of cases reported in the literature, the course of juvenile Huntington’s disease significantly differs from adult onset and shows significant interpatient variability, making every case unique. Case presentation Our study aims to highlight the complexity and diversity of rare juvenile Huntington’s disease. We report cases of two Caucasian patients with chronic tics referred to the Huntington’s Disease Competence Center of Vilnius University Hospital Santaros Klinikos with suspicion of juvenile Huntington’s disease due to the appearance of chronic motor tics, and behavior problems. The diagnosis of juvenile Huntington’s disease was confirmed on both clinical and genetic grounds. In both cases described, the patients developed symptoms in all three main groups: motor, cognitive, and psychiatric. However, the first patient was experiencing more severe psychiatric symptoms; in the second case, motor symptoms (rigidity, tremor) were more prominent. In both cases, apathy was one of the first symptoms and affected patients’ motivation to participate in treatment actively. These two case descriptions serve as an important message for clinicians seeing patients with chronic tics and gradually worsening mood and behavior, indicating the need to investigate them for rare genetic disorders. Conclusions Description of these two clinical cases of juvenile Huntington’s disease provides insight into how differently it manifests and progresses in young patients and the difficulties the patients and their families face. There were different but painful ways for families to accept the diagnosis. Because the disease inevitably affects the patient’s closest ones, it is crucial to also provide adequate psychological and social support to all the family members. Establishment of multidisciplinary specialist centers for Huntington’s disease, as demonstrated by our experience, not only allows timely diagnosis and treatment plans but also ensures thorough disease management and care for patients and systematic support for their families.


2017 ◽  
Vol 7 (5) ◽  
pp. 307-315 ◽  
Author(s):  
Amelia D Moser ◽  
Eric Epping ◽  
Patricia Espe-Pfeifer ◽  
Erin Martin ◽  
Leah Zhorne ◽  
...  

1995 ◽  
Vol 17 (4) ◽  
pp. 312-315 ◽  
Author(s):  
Ignacio Madrazo ◽  
Rebecca E. Franco-Bourland ◽  
Hugo Castrejon ◽  
Carlos Cuevas ◽  
Feggy Ostrosky-Solis

2008 ◽  
Author(s):  
Helen M. Brewer ◽  
Virginia Eatough ◽  
Jonathan A. Smith ◽  
Cath A. Stanley ◽  
Neil W. Glendinning ◽  
...  

2020 ◽  
Vol 91 (6) ◽  
pp. 622-630
Author(s):  
Kate L Harris ◽  
Wei-Li Kuan ◽  
Sarah L Mason ◽  
Roger A Barker

ObjectivesAlterations in dopamine neurotransmission underlie some of the clinical features of Huntington’s disease (HD) and as such are a target for therapeutic intervention, especially for the treatment of chorea and some behavioural problems. However, justification for such an intervention is mainly based on case reports and small open label studies and the effects these drugs have on cognition in HD remain unclear.MethodsIn this study, we used the Enroll-HD observational database to assess the effects of antidopaminergic medication on motor, psychiatric and cognitive decline, over a 3-year period. We first looked at the annual rate of decline of a group of HD patients taking antidopaminergic medication (n=466) compared with an untreated matched group (n=466). The groups were matched on specified clinical variables using propensity score matching. Next, we studied a separate group of HD patients who were prescribed such medications part way through the study (n=90) and compared their rate of change before and after the drugs were introduced and compared this to a matched control group.ResultsWe found that HD patients taking antidopaminergic medication had a slower progression in chorea and irritability compared with those not taking such medications. However, this same group of patients also displayed significantly greater rate of decline in a range of cognitive tasks.ConclusionIn conclusion we found that antidopaminergic treatment is associated with improvements in the choreic movements and irritability of HD but worsens cognition. However, further research is required to prospectively investigate this and whether these are causally linked, ideally in a double-blind placebo-controlled trial.


2018 ◽  
Vol 17 (11) ◽  
pp. 986-993 ◽  
Author(s):  
Caterina Fusilli ◽  
Simone Migliore ◽  
Tommaso Mazza ◽  
Federica Consoli ◽  
Alessandro De Luca ◽  
...  

2018 ◽  
Vol 07 (01) ◽  
pp. 021-023
Author(s):  
Fatma Feki ◽  
Chahnez Triki ◽  
Nesrine Amara

AbstractJuvenile Huntington's disease (JHD) shares many general clinical features with the adult form. One important difference is that JHD patients experience more epileptic manifestations, sometimes difficult to control. We describe an atypical clinical picture of a genetically confirmed JHD patient diagnosed during evaluation for a progressive myoclonic epilepsy. A female patient with a family history of psychiatric disorders developed recurrent drug-resistant myoclonic seizures at the age of 6 years, followed by extrapyramidal symptoms (rigidity and dystonia). Cognitive impairment, akinetic rigidity syndrome, and dystonia were noticed at the age of 10 years. Epileptiform abnormalities were noted in ictal electroencephalography. Magnetic resonance imaging showed brain atrophy. Genetic testing for HD confirmed the diagnosis. JHD can initially manifest as myoclonic epilepsy. A DNA testing should be performed if clinical history is suggestive.


Sign in / Sign up

Export Citation Format

Share Document